Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00458_nanopub.RAtBb7n7uE1vTNFYbgZFYELAk9Ar0EGnY8DJD3wsO_CT4#assertion>. }
Showing items 1 to 31 of
31
with 100 items per page.
- drugbank:DB00458 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00458 label "Imipramine [drugbank:DB00458]" assertion.
- drugbank:DB00458 seeAlso imip.htm assertion.
- drugbank:DB00458 seeAlso tof1448.shtml assertion.
- drugbank:DB00458 seeAlso imipramine.html assertion.
- drugbank:DB00458 seeAlso DB00458 assertion.
- drugbank:DB00458 description "Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. See toxicity section below for a complete listing of side effects. Imipramine may be used to treat depression and nocturnal enuresis in children. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD)." assertion.
- drugbank:DB00458 identifier "drugbank:DB00458" assertion.
- drugbank:DB00458 title "Imipramine" assertion.
- drugbank:DB00458 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46507351 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-pubchemcompound pubchem.compound:3696 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-pdb pdb:IXX assertion.
- drugbank:DB00458 drugbank_vocabulary:x-chemspider chemspider:3568 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-cas cas:50-49-7 assertion.
- drugbank:DB00458 drugbank_vocabulary:drugbank-id "APRD00672" assertion.
- drugbank:DB00458 drugbank_vocabulary:drugbank-id "DB00458" assertion.
- drugbank:DB00458 drugbank_vocabulary:drugbank-id "DB08002" assertion.
- drugbank:DB00458 bio2rdf_vocabulary:x-identifiers.org DB00458 assertion.
- drugbank:DB00458 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00458" assertion.
- drugbank:DB00458 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00458 bio2rdf_vocabulary:identifier "DB00458" assertion.
- drugbank:DB00458 drugbank_vocabulary:x-wikipedia wikipedia:Imipramine assertion.
- drugbank:DB00458 drugbank_vocabulary:x-pharmgkb pharmgkb:PA449969 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-kegg kegg:C07049 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-dpd dpd:726397 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-chebi chebi:5881 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-atc atc:N06AA03 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-ahfs ahfs:28:16.04.28 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-ndc ndc:53489-330-07 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-iuphar iuphar:357 assertion.
- drugbank:DB00458 drugbank_vocabulary:x-gtp gtp:357 assertion.